Literature DB >> 29923005

Therapeutic Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Neuroinflammation and Neuroplasticity in Patients with Parkinson's Disease: a Placebo-Controlled Study.

L I Aftanas1,2, M M Gevorgyan3, S Ya Zhanaeva3, S S Dzemidovich3, K I Kulikova3, E L Al'perina3, K V Danilenko3,4, G V Idova3,4.   

Abstract

The parallel placebo-controlled study examined the therapeutic effects of dual-target repetitive transcranial magnetic stimulation (rTMS) of the motor cortex (bilaterally) and the left prefrontal cortex (dorsolaterally) on spontaneous and mitogen-stimulating synthesis of pro- and anti-inflammatory cytokines by the blood cells and the level of brain-derived neurotrophic factor (BDNF) in blood serum of patients with Parkinson's disease. The significantly steeper positive clinical dynamics (assessed by UPRSD scale) observed in rTMS group in comparison with the placebo group was accompanied by a significant drop in spontaneous production of proinflammatory cytokines IFNγ and IL-17A. rTMS produced no significant effect on serum BDNF. The possible mechanisms of rTMS therapeutic action on the level of cytokines associated with neuroinflammation in patients with Parkinson's disease are discussed.

Entities:  

Keywords:  BDNF; Parkinson’s disease; high-frequency repetitive transcranial magnetic stimulation (rTMS); pro- and anti-inflammatory cytokines

Mesh:

Substances:

Year:  2018        PMID: 29923005     DOI: 10.1007/s10517-018-4128-4

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  13 in total

1.  Effect of Repetitive Transcranial Magnetic Stimulation on Serum Levels of Steroid Adrenal Hormones in Parkinson's Disease: Sex Differences.

Authors:  L I Aftanas; S Ya Zhanaeva; E L Al'perina; G V Idova; M M Gevorgyan; S S Dzemidovich; K I Kulikova
Journal:  Bull Exp Biol Med       Date:  2022-07-19       Impact factor: 0.737

2.  Intermittent Theta Burst Stimulation Ameliorates Cognitive Deficit and Attenuates Neuroinflammation via PI3K/Akt/mTOR Signaling Pathway in Alzheimer's-Like Disease Model.

Authors:  Andjela Stekic; Milica Zeljkovic; Marina Zaric Kontic; Katarina Mihajlovic; Marija Adzic; Ivana Stevanovic; Milica Ninkovic; Ivana Grkovic; Tihomir V Ilic; Nadezda Nedeljkovic; Milorad Dragic
Journal:  Front Aging Neurosci       Date:  2022-05-17       Impact factor: 5.702

3.  Combination of Human Mesenchymal Stem Cells and Repetitive Transcranial Magnetic Stimulation Enhances Neurological Recovery of 6-Hydroxydopamine Model of Parkinsonian's Disease.

Authors:  Ji Yong Lee; Hyun Soo Kim; Sung Hoon Kim; Han-Soo Kim; Byung Pil Cho
Journal:  Tissue Eng Regen Med       Date:  2020-01-22       Impact factor: 4.169

4.  Guidelines for TMS/tES clinical services and research through the COVID-19 pandemic.

Authors:  Marom Bikson; Colleen A Hanlon; Adam J Woods; Bernadette T Gillick; Leigh Charvet; Claus Lamm; Graziella Madeo; Adrienn Holczer; Jorge Almeida; Andrea Antal; Mohammad Reza Ay; Chris Baeken; Daniel M Blumberger; Salvatore Campanella; Joan A Camprodon; Lasse Christiansen; Colleen Loo; Jennifer T Crinion; Paul Fitzgerald; Luigi Gallimberti; Peyman Ghobadi-Azbari; Iman Ghodratitoostani; Roland H Grabner; Gesa Hartwigsen; Akimasa Hirata; Adam Kirton; Helena Knotkova; Evgeny Krupitsky; Paola Marangolo; Ester M Nakamura-Palacios; Weronika Potok; Samir K Praharaj; Christian C Ruff; Gottfried Schlaug; Hartwig R Siebner; Charlotte J Stagg; Axel Thielscher; Nicole Wenderoth; Ti-Fei Yuan; Xiaochu Zhang; Hamed Ekhtiari
Journal:  Brain Stimul       Date:  2020-05-12       Impact factor: 8.955

5.  Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders.

Authors:  Samuel F Yanuck
Journal:  Front Psychiatry       Date:  2019-10-03       Impact factor: 4.157

Review 6.  Update on the Use of Transcranial Electrical Brain Stimulation to Manage Acute and Chronic COVID-19 Symptoms.

Authors:  Giuseppina Pilloni; Marom Bikson; Bashar W Badran; Mark S George; Steven A Kautz; Alexandre Hideki Okano; Abrahão Fontes Baptista; Leigh E Charvet
Journal:  Front Hum Neurosci       Date:  2020-11-12       Impact factor: 3.169

Review 7.  Applications of Non-invasive Neuromodulation for the Management of Disorders Related to COVID-19.

Authors:  Abrahão Fontes Baptista; Adriana Baltar; Alexandre Hideki Okano; Alexandre Moreira; Ana Carolina Pinheiro Campos; Ana Mércia Fernandes; André Russowsky Brunoni; Bashar W Badran; Clarice Tanaka; Daniel Ciampi de Andrade; Daniel Gomes da Silva Machado; Edgard Morya; Eduardo Trujillo; Jaiti K Swami; Joan A Camprodon; Katia Monte-Silva; Katia Nunes Sá; Isadora Nunes; Juliana Barbosa Goulardins; Marom Bikson; Pedro Sudbrack-Oliveira; Priscila de Carvalho; Rafael Jardim Duarte-Moreira; Rosana Lima Pagano; Samuel Katsuyuki Shinjo; Yossi Zana
Journal:  Front Neurol       Date:  2020-11-25       Impact factor: 4.003

8.  Oxolipidomics profile in major depressive disorder: Comparing remitters and non-remitters to repetitive transcranial magnetic stimulation treatment.

Authors:  Hannah Stirton; Benjamin P Meek; Andrea L Edel; Zahra Solati; Arun Surendran; Harold Aukema; Mandana Modirrousta; Amir Ravandi
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

Review 9.  The Role of Repetitive Transcranial Magnetic Stimulation for Enhancing the Quality of Life in Parkinson's Disease: A Systematic Review.

Authors:  Ashima Nehra; Priya S Sharma; Avneesh Narain; Amit Kumar; Swati Bajpai; Roopa Rajan; Nand Kumar; Vinay Goyal; Achal K Srivastava
Journal:  Ann Indian Acad Neurol       Date:  2020-05-21       Impact factor: 1.383

Review 10.  Multisite non-invasive brain stimulation in Parkinson's disease: A scoping review.

Authors:  Camila Beatriz da Silva Machado; Letícia Maria da Silva; Alessandra Feitosa Gonçalves; Palloma Rodrigues de Andrade; Cristina Katya Torres Teixeira Mendes; Thais Josy Castro Freire de Assis; Clécio de Oliveira Godeiro Júnior; Suellen Marinho Andrade
Journal:  NeuroRehabilitation       Date:  2021       Impact factor: 2.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.